These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1390121

  • 1. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA, Ferguson J.
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [Abstract] [Full Text] [Related]

  • 2. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M, Ros AM.
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A, Hofer A, Legat F, Kerl H, Wolf P.
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [Abstract] [Full Text] [Related]

  • 4. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G.
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [Abstract] [Full Text] [Related]

  • 5. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG, Zane C, Carlino A, De Panfilis G.
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [Abstract] [Full Text] [Related]

  • 6. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A, Ortel B, Rappersberger K, Hönigsmann H.
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis.
    Vongthongsri R, Konschitzky R, Seeber A, Treitl C, Hönigsmann H, Tanew A.
    J Am Acad Dermatol; 2006 Oct; 55(4):627-31. PubMed ID: 17010742
    [Abstract] [Full Text] [Related]

  • 8. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
    Hönigsmann H, Jaschke E, Gschnait F, Brenner W, Fritsch P, Wolff K.
    Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
    [Abstract] [Full Text] [Related]

  • 9. PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study.
    Schiener R, Gottlöber P, Müller B, Williams S, Pillekamp H, Peter RU, Kerscher M.
    Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):62-7. PubMed ID: 15752122
    [Abstract] [Full Text] [Related]

  • 10. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
    Nimkulrat P, Leenutaphong V, Sudtim S.
    J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
    [Abstract] [Full Text] [Related]

  • 11. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.
    Aubin F, Makki S, Humbert P, Muret P, Agache P.
    Arch Dermatol Res; 1994 Oct; 286(1):30-4. PubMed ID: 8141609
    [Abstract] [Full Text] [Related]

  • 12. Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.
    Thune P.
    Acta Derm Venereol; 1978 Oct; 58(2):149-51. PubMed ID: 76395
    [Abstract] [Full Text] [Related]

  • 13. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
    Nørgaard M, Hueg B, Staberg B.
    Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
    [Abstract] [Full Text] [Related]

  • 14. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
    Man I, McKinlay J, Dawe RS, Ferguson J, Ibbotson SH.
    J Am Acad Dermatol; 2003 Jul; 49(1):59-64. PubMed ID: 12833009
    [Abstract] [Full Text] [Related]

  • 15. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
    Hannuksela-Svahn A, Pukkala E, Koulu L, Jansén CT, Karvonen J.
    J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
    [Abstract] [Full Text] [Related]

  • 16. [The pharmacokinetic and toxicologic profile of 8-methoxypsoralen. The basis for safe and effective PUVA therapy].
    Schmid J, Brickl R, Koss FW.
    Derm Beruf Umwelt; 1988 May; 36(6):177-85. PubMed ID: 3069432
    [Abstract] [Full Text] [Related]

  • 17. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.
    Weber F, Schmuth M, Sepp N, Fritsch P.
    Acta Derm Venereol; 2005 May; 85(4):329-32. PubMed ID: 16191854
    [Abstract] [Full Text] [Related]

  • 18. [Clinical experience with the 8-methoxypsoralen-UVA therapy (photochemotherapy) of psoriasis].
    Hofmann C, Plewig G, Braun-Falco O.
    Hautarzt; 1976 Dec; 27(12):588-94. PubMed ID: 1010746
    [Abstract] [Full Text] [Related]

  • 19. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.
    Asawanonda P, Amornpinyokeit N, Nimnuan C.
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):50-5. PubMed ID: 18181973
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
    Engin B, Oguz O.
    Int J Dermatol; 2005 Apr; 44(4):337-9. PubMed ID: 15811091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.